Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback